News

Video

T-DXd in HER2 Mutated Advanced NSCLC

Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.